Karyopharm Therapeutics (KPTI) Change in Inventory (2019 - 2025)
Karyopharm Therapeutics' (KPTI) quarterly Change in Inventory came in at $72000.0 in Q4 2025, up 7.46% YoY from $67000.0 in Q4 2024, and up 107.02% on a QoQ basis from -$1.0 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Change in Inventory (2019 - 2025) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 7 years of Change in Inventory data on file, last reported at $72000.0 in Q4 2025.
- Quarterly Change in Inventory rose 7.46% year-over-year to $72000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$701000.0 (down 141.33% YoY) and the FY2025 annual result came in at -$701000.0, down 141.33% from the prior year.
- Change in Inventory grew to $72000.0 in Q4 2025, from -$1.0 million in the prior quarter.
- In the past five years, Change in Inventory ranged from a high of $1.2 million in Q3 2024 to a low of -$1.0 million in Q3 2025.
- A 5-year average of $69700.0 and a median of $2500.0 in 2022 frame the typical range for Change in Inventory.
- Annual changes were most pronounced in 2022 — Change in Inventory jumped 743.8% — and 2025, when it sank 185.79%.
- Tracing KPTI's Change in Inventory over 5 years: stood at $77000.0 in 2021, then sank by 132.47% to -$25000.0 in 2022, then plunged by 148.0% to -$62000.0 in 2023, then surged by 208.06% to $67000.0 in 2024, then rose by 7.46% to $72000.0 in 2025.
- The last three Change in Inventory figures came in at $72000.0 (Q4 2025), -$1.0 million (Q3 2025), and $223000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 28.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 132.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 47.15 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -280,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 135.26 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 12.97 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 72,000.00 |
| Dec 31, 2025 | 72,000.00 |
| Sep 30, 2025 | -1.03 Mn |
| Sep 30, 2025 | -1.03 Mn |
| Jun 30, 2025 | 223,000.00 |
| Jun 30, 2025 | 223,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Dec 31, 2024 | 67,000.00 |
| Dec 31, 2024 | 67,000.00 |
| Sep 30, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | 707,000.00 |
| Jun 30, 2024 | 707,000.00 |
| Mar 31, 2024 | -274,000.00 |
| Mar 31, 2024 | -274,000.00 |
| Dec 31, 2023 | -62,000.00 |
| Dec 31, 2023 | -62,000.00 |
| Sep 30, 2023 | -567,000.00 |
| Sep 30, 2023 | -567,000.00 |